Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

被引：1
|
作者：
Mustacchi, G.
Bines, J.
Alba, E.
Cortes, P.
Doval, D.
de Ducla, S.
Button, P.
Gligorov, J.
机构：
[1] Univ Trieste, Trieste, Italy
[2] Inst Nacl Canc, Rio De Janeiro, Brazil
[3] Hosp Univ Clin Virgen Victoria, Malaga, Spain
[4] Univ Hosp Santa Maria, Lisbon, Portugal
[5] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Roche Prod Ltd, Dee Why, Australia
[8] IC UPMC, APHP Tenon, Paris, France
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P5-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-15-06
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C.
    Gligorov, J.
    Marschner, N.
    Puglisi, F.
    Vrdoljak, E.
    Castan, J. Cortes
    de Ducla, S.
    Deurloo, R.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies
    Glaspy, J.
    Dieras, V.
    Brufsky, A.
    Miles, D. W.
    Phan, S. C.
    O'Shaughnessy, J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 202 - 202
  • [43] Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events.
    Robert, N.
    Dieras, V
    Glaspy, J.
    Brufsky, A.
    Miller, K. D.
    Miles, D. W.
    Koralewski, P.
    Bhattacharya, S.
    Phan, S-C
    CANCER RESEARCH, 2009, 69 (24) : 850S - 851S
  • [44] Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
    O'Shaughnessy, J.
    Dieras, V
    Glaspy, J.
    Brufsky, A.
    Miller, K. D.
    Miles, D. W.
    Koralewski, P.
    Phan, S-C
    Bhattacharya, S.
    CANCER RESEARCH, 2009, 69 (24) : 512S - 512S
  • [45] Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) plus capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy
    Urruticoechea, Ander
    Rizwanullah, Mohammed
    Im, Seock-Ah
    Ruiz, Antonio Carlos Sanchez
    Lang, Istvan
    Tomasello, Gianluca
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Eng-Wong, Jennifer
    Munoz, Montserrat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).
    von Minckwitz, G.
    Cortes, J.
    Gligorov, J.
    Marschner, N. W.
    Puglisi, F.
    Vrdoljak, E.
    Duenne, A-A
    Zielinski, C.
    CANCER RESEARCH, 2011, 71
  • [47] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] First-line therapy with metronomic capecitabine (mC) plus docetaxel (D) followed by mC as maintenance for patients with HER2-negative metastatic breast cancer (MBC): Preliminary analysis of a monocentric phase II trial
    Aurilio, G.
    Sciandivasci, A.
    Munzone, E.
    Riva, D. F.
    Radice, D.
    Bertolini, F.
    Minchella, I.
    Cullura, D.
    Curigliano, G.
    Zampino, M. G.
    Goldhirsch, A.
    Nole, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, G.
    Gampenrieder, S. P.
    Voskova, D.
    Petzer, A.
    Hubalek, M.
    Petru, E.
    Hartmann, B.
    Andel, J.
    Balic, M.
    Melchardt, T.
    Ulmer, H.
    Mlineritsch, B.
    Greil, R.
    CANCER RESEARCH, 2017, 77
  • [50] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, G.
    Gampenrieder, S. P.
    Voskova, D.
    Petzer, A.
    Hubalek, M.
    Petru, E.
    Hartmann, B.
    Andel, J.
    Balic, M.
    Melchardt, T.
    Mlineritsch, B.
    Greil, R.
    ANNALS OF ONCOLOGY, 2016, 27
12345